Search

Your search keyword '"Giordano, Giulio"' showing total 22 results
Start Over Author "Giordano, Giulio" Publication Year Range Last 3 years
22 results on '"Giordano, Giulio"'

6. Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort

Author

Lucchesi, Alessandro, primary, Lovrencic, Barbara, additional, McDonald, Vickie, additional, Newland, Adrian, additional, Morgan, Mervyn, additional, Eriksson, Daniel, additional, Wilson, Koo, additional, Giordano, Giulio, additional, Carli, Giuseppe, additional, Geldman, Emma, additional, Daykin-Pont, Owen, additional, Prince, Samantha, additional, and Napolitano, Mariasanta, additional

Published
2023
Full Text
View/download PDF

9. Autoimmune hemolytic anemia during pregnancy and puerperium:an international multicenter experience

Author

Fattizzo, Bruno, Bortolotti, Marta, Fantini, Norma N., Glenthøj, Andreas, Michel, Marc, Napolitano, Mariasanta, Raso, Simona, Chen, Frederick, McDonald, Vickie, Murakhovskaya, Irina, Vos, Josephine Mathilde Iris, Patriarca, Andrea, Mingot-Castellano, Maria Eva, Giordano, Giulio, Scarrone, Margherita, González-López, Tomás José, Trespidi, Laura, Prati, Daniele, Barcellini, Wilma, Fattizzo, Bruno, Bortolotti, Marta, Fantini, Norma N., Glenthøj, Andreas, Michel, Marc, Napolitano, Mariasanta, Raso, Simona, Chen, Frederick, McDonald, Vickie, Murakhovskaya, Irina, Vos, Josephine Mathilde Iris, Patriarca, Andrea, Mingot-Castellano, Maria Eva, Giordano, Giulio, Scarrone, Margherita, González-López, Tomás José, Trespidi, Laura, Prati, Daniele, and Barcellini, Wilma

Abstract

Relapsing or occurring de novo autoimmune hemolytic anemia (AIHA) during pregnancy or puerperium is a poorly described condition. Here, we report 45 pregnancies in 33 women evaluated at 12 centers from 1997 to 2022. Among the 20 women diagnosed with AIHA before pregnancy, 10 had a relapse. An additional 13 patients developed de novo AIHA during gestation/puerperium (2 patients had AIHA relapse during a second pregnancy). Among 24 hemolytic events, anemia was uniformly severe (median Hb, 6.4 g/dL; range, 3.1-8.7) and required treatment in all cases (96% steroids ± intravenous immunoglobulin, IVIG, 58% transfusions). Response was achieved in all patients and was complete in 65% of the cases. Antithrombotic prophylaxis was administered to 8 patients (33%). After delivery, rituximab was administered to 4 patients, and cyclosporine was added to 1 patient. The rate of maternal complications, including premature rupture of membranes, placental detachment, and preeclampsia, was 15%. Early miscarriages occurred in 13% of the pregnancies. Fetal adverse events (22% of cases) included respiratory distress, fetal growth restriction, preterm birth, AIHA of the newborn, and 2 perinatal deaths. In conclusion, the occurrence of AIHA does not preclude the ability to carry out a healthy pregnancy, provided close monitoring, prompt therapy, and awareness of potential maternal and fetal complications.

Published
2023

10. AUTOIMMUNE HEMOLYTIC ANEMIA DURING PREGNANCY AND PUERPERIUM: AN INTERNATIONAL MULTI-CENTER EXPERIENCE

Author

Fattizzo, Bruno, primary, Bortolotti, Marta, additional, Fantini, Norma Nadia, additional, Glenthøj, Andreas, additional, Michel, Marc, additional, Napolitano, Mariasanta, additional, Raso, Simona, additional, Chen, Frederick, additional, McDonald, Vickie, additional, Murakhovskaya, Irina, additional, Vos, Josephine M.I., additional, Patriarca, Andrea, additional, Mingot-Castellano, Maria Eva, additional, Giordano, Giulio, additional, Scarrone, Margherita, additional, Gonzalez-Lopez, Tomas Jose, additional, Trespidi, Laura, additional, Prati, Daniele, additional, and Barcellini, Wilma, additional

Published
2023
Full Text
View/download PDF

11. Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Author

Fattizzo, Bruno, Bortolotti, Marta, Fantini, Norma N., Glenthøj, Andreas, Michel, Marc, Napolitano, Mariasanta, Raso, Simona, Chen, Frederick, McDonald, Vickie, Murakhovskaya, Irina, Vos, Josephine Mathilde Iris, Patriarca, Andrea, Mingot-Castellano, Maria Eva, Giordano, Giulio, Scarrone, Margherita, González-López, Tomás José, Trespidi, Laura, Prati, Daniele, and Barcellini, Wilma

Published
2023
Full Text
View/download PDF

12. Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

Author

Lucchesi, Alessandro, primary, Napolitano, Roberta, additional, Bochicchio, Maria Teresa, additional, Simonetti, Giorgia, additional, Micucci, Giorgia, additional, Poggiaspalla, Monica, additional, Di Battista, Valeria, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, Giordano, Giulio, additional, Foca, Flavia, additional, Catani, Lucia, additional, and Napolitano, Mariasanta, additional

Published
2022
Full Text
View/download PDF

13. Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience

Author

Bortolotti, Marta, primary, Fantini, Norma, additional, Glenthøj, Andreas, additional, Michel, Marc, additional, Napolitano, Mariasanta, additional, Raso, Simona, additional, Chen, Frederick, additional, McDonald, Vickie, additional, Murakhovskaya, Irina, additional, Vos, Josephine M.I., additional, Patriarca, Andrea, additional, Mingot, Maria Eva, additional, Giordano, Giulio, additional, Scarrone, Margherita, additional, Trespidi, Laura, additional, Prati, Daniele, additional, Barcellini, Wilma, additional, and Fattizzo, Bruno, additional

Published
2022
Full Text
View/download PDF

14. Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience

Author

Fattizzo, Bruno, primary, Cecchi, Nicola, additional, Bortolotti, Marta, additional, Giordano, Giulio, additional, Patriarca, Andrea, additional, Glenthøj, Andreas, additional, Cantoni, Silvia, additional, Capecchi, Marco, additional, Chen, Frederick, additional, Mingot-Castellano, Maria Eva, additional, Napolitano, Mariasanta, additional, Frederiksen, Henrik, additional, Gonzaléz-Lopez, Tomàs José, additional, and Barcellini, Wilma, additional

Published
2022
Full Text
View/download PDF

16. Thrombopoietin receptor agonists in adult Evans syndrome:an international multicenter experience

Author

Fattizzo, Bruno, Cecchi, Nicola, Bortolotti, Marta, Giordano, Giulio, Patriarca, Andrea, Glenthøj, Andreas, Cantoni, Silvia, Capecchi, Marco, Chen, Frederick, Mingot-Castellano, Maria Eva, Napolitano, Mariasanta, Frederiksen, Henrik, Gonzaléz-Lopez, Tomàs José, Barcellini, Wilma, Fattizzo, Bruno, Cecchi, Nicola, Bortolotti, Marta, Giordano, Giulio, Patriarca, Andrea, Glenthøj, Andreas, Cantoni, Silvia, Capecchi, Marco, Chen, Frederick, Mingot-Castellano, Maria Eva, Napolitano, Mariasanta, Frederiksen, Henrik, Gonzaléz-Lopez, Tomàs José, and Barcellini, Wilma

Published
2022

18. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers

Author

Tiscia, Giovanni, primary, Sartori, Maria Teresa, additional, Giuffrida, Gaetano, additional, Ostuni, Angelo, additional, Cascavilla, Nicola, additional, Nicolosi, Daniela, additional, Battista, Cosima, additional, Santeramo, Teresa Maria, additional, Melillo, Lorella, additional, Giordano, Giulio, additional, Cappucci, Filomena, additional, Fischetti, Lucia, additional, Chinni, Elena, additional, Tarantini, Giuseppe, additional, Cerbo, Anna, additional, Bertomoro, Antonella, additional, Fabris, Fabrizio, additional, and Grandone, Elvira, additional

Published
2021
Full Text
View/download PDF

19. Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience

Author

Bruno Fattizzo, Nicola Cecchi, Marta Bortolotti, Giulio Giordano, Andrea Patriarca, Andreas Glenthøj, Silvia Cantoni, Marco Capecchi, Frederick Chen, Maria Eva Mingot-Castellano, Mariasanta Napolitano, Henrik Frederiksen, Tomàs José Gonzaléz-Lopez, Wilma Barcellini, [Fattizzo, Bruno] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Sforza 35, I-20122 Milan, Italy, [Cecchi, Nicola] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Sforza 35, I-20122 Milan, Italy, [Bortolotti, Marta] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Sforza 35, I-20122 Milan, Italy, [Capecchi, Marco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Sforza 35, I-20122 Milan, Italy, [Barcellini, Wilma] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Sforza 35, I-20122 Milan, Italy, [Fattizzo, Bruno] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy, [Cecchi, Nicola] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy, [Bortolotti, Marta] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy, [Capecchi, Marco] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy, [Giordano, Giulio] Med Serv & Ambulatorio Ematol Osped Riferimento, Unita Operat Complessa UOC, Campobasso, Italy, [Patriarca, Andrea] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy, [Patriarca, Andrea] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark, [Cantoni, Silvia] Niguarda Canc Ctr, Azienda Socio Sanitaria Territoriale ASST Grande, Milan, Italy, [Chen, Frederick] Clin Haematol, Barts Hlth Natl Hlth Serv NHS Trust & Queen Mary, London, England, [Mingot-Castellano, Maria Eva] Univ Virgen Rocio, Area Banco Sangre Establecimiento Tejidos Hosp, Serv Hematol, Seville, Spain, [Napolitano, Mariasanta] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties ProMISE, Palermo, Italy, [Frederiksen, Henrik] Odense Univ Hosp, Dept Hematol, Odense, Denmark, [Jose Gonzalez-Lopez, Tomas] Hosp Univ Burgos, Serv Hematol, Burgos, Spain, Italian Ministry of Health Current Research Grant, Fattizzo, Bruno, Cecchi, Nicola, Bortolotti, Marta, Giordano, Giulio, Patriarca, Andrea, Glenthøj, Andrea, Cantoni, Silvia, Capecchi, Marco, Chen, Frederick, Mingot-Castellano, Maria Eva, Napolitano, Mariasanta, Frederiksen, Henrik, Gonzaléz-Lopez, Tomàs José, and Barcellini, Wilma

Subjects
Adult, Purpura, Thrombocytopenic, Idiopathic, Recombinant Fusion Proteins, Immunology, Severe thrombocytopenia, Cell Biology, Hematology, Receptors, Fc, Biochemistry, Benzoates, Thrombocytopenia, Benzoate, Hydrazines, Thrombopoietin, Eltrombopag, Hydrazine, Humans, Anemia, Hemolytic, Autoimmune, Receptors, Thrombopoietin, Human, Recombinant Fusion Protein
Published
2022
Full Text
View/download PDF

20. Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms

Author

Giulio Giordano, Mariasanta Napolitano, Michele Cellurale, Paola Di Carlo, Gerardo Musuraca, Giorgia Micucci, Alessandro Lucchesi, Giordano, Giulio, Napolitano, Mariasanta, Cellurale, Michele, Di Carlo, Paola, Musuraca, Gerardo, Micucci, Giorgia, and Lucchesi, Alessandro

Subjects
Circulating endothelial cell, cardiovascular system, Myeloproliferative neoplasm, Medicine (miscellaneous), myeloproliferative neoplasms, portal vein thrombosis, circulating endothelial cells, recanalization, Recanalization, Portal vein thrombosi
Abstract

Circulating endothelial cells (CECs) are viable, apoptotic or necrotic cells, identified by CD 146 surface antigen expression, considered a biomarker of thrombotic risk, given their active role in inflammatory, procoagulant and immune processes of the vascular compartment. Growing evidence establishes that CECs are also involved in the pathogenesis of several hematological and solid malignancies. The primary aim of this study was to verify if CEC levels could predict both the course and treatment responses of splanchnic vein thrombosis (SVT), either in patients affected by myeloproliferative neoplasms (MPNs) or liver disease. Thus, a retrospective multicenter study was performed; fifteen patients receiving anticoagulant oral treatment with vitamin k antagonists (VKA) for SVT were evaluated. Nine patients were affected by MPN, and all of them received cytoreduction in addition to anticoagulant therapy; four of these patients had primary myelofibrosis (PMF) and were treated with ruxolitinib (RUX), and one patient with primary myelofibrosis, two patients with essential thrombocythemia (ET), and two patients with polycythemia vera (PV) were treated with hydroxyurea (HU). Six patients affected by liver diseases (three with liver cirrhosis and three with hepatocellular carcinoma) were included as the control group. CECs were assayed by flow cytometry on peripheral blood at specific time points, for up to six months after enrollment. The CEC levels were related to C-reactive protein (CRP) levels, splenic volume reduction, and thrombus recanalization, mainly in MPN patients. In patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC), for which the mechanism of SVT development is quite different, the relationship between CEC and SV reduction was absent. In conclusion, the CEC levels showed a significant correlation with the extent of venous thrombosis and endothelial cell damage in myeloproliferative neoplasm patients with splanchnic vein thrombosis. Although preliminary, these results show how monitoring CEC levels during cytoreductive and anticoagulant treatments may be useful to improve SVT outcome in MPN patients.

Published
2022

21. Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements

Author

Marta Mattana, Riccardo Tomasello, Claudia Cammarata, Paola Di Carlo, Teresa Fasciana, Giulio Giordano, Alessandro Lucchesi, Sergio Siragusa, Mariasanta Napolitano, Mattana, Marta, Tomasello, Riccardo, Cammarata, Claudia, Di Carlo, Paola, Fasciana, Teresa, Giordano, Giulio, Lucchesi, Alessandro, Siragusa, Sergio, and Napolitano, Mariasanta

Subjects
sepsis, Microbiology (medical), enterocoliti, induced inflammasome activation, coagulation derangement, Virology, Clostridium difficile, Microbiology
Abstract

C. difficile enterocolitis (CDAC) is the most common hospital infection, burdened by an increased incidence of coagulation-related complications such as deep vein thrombosis (DVT) and disseminated intravascular coagulation (DIC) as well as a significant sepsis-related mortality. In this review, we analyzed the available data concerning the correlation between coagulation complications related to C. difficile infection (CDI) and inflammasome activation, in particular the pyrin-dependent one. The little but solid available preclinical and clinical evidence shows that inflammasome activation increases the risk of venous thromboembolism (VTE). As proof of this, it has been observed that in vitro inhibition of the molecules (e.g., tissue factor) mainly involved in coagulation activation could block the process. In vivo studies show that it could be possible to reduce the incidence of complications associated with C. difficile infection (CDI) and mortality due to a state of hypercoagulability. A personalized therapeutic approach to reduce the inflammatory activity and prevent thromboembolic complications could be preliminarily defined to reduce mortality.

Published
2022
Full Text
View/download PDF

22. Global hemostasis assays in acute myeloid leukemia: results of an observational prospective study.

Author

Raso S, Lucchesi A, Sardo M, Annibali O, Sucato V, Ciaccio M, Vitale S, Dolce A, Giordano G, Siragusa S, and Napolitano M

Subjects
Humans, Prospective Studies, Hemostasis, Blood Coagulation Tests methods, Thrombelastography methods, Hemorrhage etiology, Blood Coagulation Disorders, Thrombosis, Hemostatics, Leukemia, Myeloid, Acute
Abstract

Background: Acute myeloid leukemia (AML) is characterized by a complex spectrum of coagulopathy ranging from hemorrhagic to thrombotic symptoms. To date, platelet count (PLT) and conventional coagulation tests (CCTs) cannot predict hemorrhagic events and thrombotic risk. Thromboelastography (TEG) measures the viscoelastic properties of the clot, thus providing information on the entire process of blood coagulation. The primary aim of the study was to assess the hemostatic balance from AML diagnosis to the end of chemotherapy (CHT) by TEG., Material and Methods: Here we present the results of a prospective study enrolling newly diagnosed AML patients treated with chemotherapy. Patients had complete blood counts (CBCs), TEG and CCTs performed at three time points: 1) diagnosis (T 0 ); 2) during the first cycle of CHT (T 1 ); and 3) at the end of CHT (T 2 ). An algorithm of TEG indirectly calculated thrombin generation (TG). Patients underwent daily follow-up for bleeding and thrombotic episodes up to the time of hospital discharge or death., Results: Eighty consecutive patients were evaluated; forty were eligible for the study, and 21 completed the entire study. At T 1 , maximum amplitude (MA), TG and K-time were significantly shifted toward a hypocoagulability state compared to T 0 (p<0.05), while a hypercoagulable state at T 2 was shown by changes in α-angle, MA and TG values. Otherwise, there were no statistically significant differences in CCTs between the evaluated time points., Discussion: Overall, TEG revealed complex and dynamic coagulation abnormalities in patients with AML according to both the course of disease and therapy. Further studies are needed to investigate more fully the role of TEG in defining the hemostatic profile in patients with AML.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results